<DOC>
	<DOCNO>NCT02038777</DOCNO>
	<brief_summary>This open-label , multi-center , Phase 1 study PF-04449913 Japanese patient . PF-04449913 administer orally single agent patient select advanced hematologic malignancy , combination LDAC [ Low-Dose Ara-C ] cytarabine daunorubicin previously untreated patient AML [ Acute Myeloid Leukemia ] high-risk MDS [ Myelodysplastic Syndrome ] .</brief_summary>
	<brief_title>A Study Of PF-04449913 In Japanese Patients With Select Hematologic Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<criteria>Patients select advanced hematologic malignancy refractory , resistant intolerant prior therapy monotherapy cohort . Patients AML HighRisk MDS newly diagnose previously untreated combination cohort . ECOG [ Eastern Cooperative Oncology Group ] performance status 0 2 Adequate organ function Patients active CNS disease Patient active malignancy exception basal cell carcinoma , non melanoma skin cancer , carcinoma situ cervical Patient active , life threaten clinically significant uncontrolled systemic infection</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Hematologic Malignancies</keyword>
</DOC>